Emerging Therapy, Unmet Needs and TPP Insights

Connect with Expert

Thelansis’s “Emerging Therapy Insights” report provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Key outcomes:

  • What are the emerging therapies under development for the specific disease area in the G8 markets (US, EU5, Japan, China)?
  • What are the target patient groups and the analysis of clinical trials’ design?
  • What are the key primary and secondary endpoints, and expectations of KOLs from the therapies?
  • What is the probability of success for emerging therapies?
  • What are KOL expectations from emerging therapies to overcome the challenges of current therapies?
  • What would be the market share for studied TPPs for the specific disease area?

Reports:

February 14, 2025

Market Access and Reimbursement Insights

Follicular Lymphoma (FL) – Market Access and Reimbursement Insights Report – 2025

Thelansis’s “Follicular Lymphoma (FL) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

November 29, 2024

Epidemiology Insights and Forecast

Follicular Lymphoma (FL) – Epidemiology Insights and Forecast Report – 2020 To 2040

Thelansis’s “Follicular Lymphoma (FL) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

December 11, 2024

Emerging Therapy, Unmet Needs and TPP Insights

Follicular Lymphoma (FL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Thelansis’s “Follicular Lymphoma (FL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

February 6, 2025

Current Treatment Insights

Follicular Lymphoma (FL) – Current Treatment Insights Report – 2025

Thelansis’s “Follicular Lymphoma (FL) Current Treatment Insights Report – 2025″ describes the current treatment and management in Follicular Lymphoma. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.

November 21, 2024

Market Outlook and Forecast

Hirschsprung Disease (HD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Thelansis’s “Hirschsprung Disease (HD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hirschsprung Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

February 17, 2025

Market Access and Reimbursement Insights

Spinal Muscular Atrophy (SMA) – Market Access and Reimbursement Insights Report – 2025

Thelansis’s “Spinal Muscular Atrophy (SMA) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Explore Reports

Need customize support?

Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

Connect with Expert